CA2943367A1 - Engineered light-activated anion channel proteins and methods of use thereof - Google Patents
Engineered light-activated anion channel proteins and methods of use thereof Download PDFInfo
- Publication number
- CA2943367A1 CA2943367A1 CA2943367A CA2943367A CA2943367A1 CA 2943367 A1 CA2943367 A1 CA 2943367A1 CA 2943367 A CA2943367 A CA 2943367A CA 2943367 A CA2943367 A CA 2943367A CA 2943367 A1 CA2943367 A1 CA 2943367A1
- Authority
- CA
- Canada
- Prior art keywords
- amino acid
- seq
- acid sequence
- residue
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 167
- 108091006515 Anion channels Proteins 0.000 title claims description 585
- 102000037829 Anion channels Human genes 0.000 title claims description 585
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 902
- 229920001184 polypeptide Polymers 0.000 claims abstract description 901
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 901
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 58
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 57
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 57
- 230000036982 action potential Effects 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1198
- 235000001014 amino acid Nutrition 0.000 claims description 419
- 150000001413 amino acids Chemical group 0.000 claims description 311
- 229940024606 amino acid Drugs 0.000 claims description 309
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 180
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 144
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 140
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 133
- 238000006467 substitution reaction Methods 0.000 claims description 112
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 100
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 98
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 98
- 239000004473 Threonine Substances 0.000 claims description 98
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 97
- 235000004279 alanine Nutrition 0.000 claims description 97
- 210000004027 cell Anatomy 0.000 claims description 91
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 68
- 230000006870 function Effects 0.000 claims description 41
- 210000002569 neuron Anatomy 0.000 claims description 37
- 102220055516 rs76646066 Human genes 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 22
- 125000003729 nucleotide group Chemical group 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 18
- 239000012528 membrane Substances 0.000 claims description 16
- 230000003213 activating effect Effects 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 14
- 210000003169 central nervous system Anatomy 0.000 claims description 13
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 13
- 102220582722 Heparan sulfate glucosamine 3-O-sulfotransferase 2_E90A_mutation Human genes 0.000 claims description 12
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 210000003484 anatomy Anatomy 0.000 claims description 8
- 210000004126 nerve fiber Anatomy 0.000 claims description 8
- 210000000715 neuromuscular junction Anatomy 0.000 claims description 8
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108010062745 Chloride Channels Proteins 0.000 claims description 4
- 102000011045 Chloride Channels Human genes 0.000 claims description 4
- 102220064269 rs786205766 Human genes 0.000 claims 12
- 239000000203 mixture Substances 0.000 abstract description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000000926 neurological effect Effects 0.000 abstract description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 177
- 230000008172 membrane trafficking Effects 0.000 description 176
- 235000018102 proteins Nutrition 0.000 description 78
- 108090000623 proteins and genes Proteins 0.000 description 78
- 102000004169 proteins and genes Human genes 0.000 description 78
- 229940009098 aspartate Drugs 0.000 description 16
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 13
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
- 235000018417 cysteine Nutrition 0.000 description 13
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 238000012421 spiking Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 239000011148 porous material Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000004200 microcrystalline wax Substances 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000002035 prolonged effect Effects 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 108091005462 Cation channels Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000903581 Natronomonas pharaonis Halorhodopsin Proteins 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108010035848 Channelrhodopsins Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- -1 but not limited to Proteins 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010291 membrane polarization Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001273 protein sequence alignment Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461972182P | 2014-03-28 | 2014-03-28 | |
| US61/972,182 | 2014-03-28 | ||
| PCT/US2015/023087 WO2015148974A2 (en) | 2014-03-28 | 2015-03-27 | Engineered light-activated anion channel proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2943367A1 true CA2943367A1 (en) | 2015-10-01 |
Family
ID=54196574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2943367A Abandoned CA2943367A1 (en) | 2014-03-28 | 2015-03-27 | Engineered light-activated anion channel proteins and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US10052383B2 (enExample) |
| EP (2) | EP3122761B1 (enExample) |
| JP (1) | JP2017511129A (enExample) |
| CN (1) | CN106459138A (enExample) |
| AU (1) | AU2015237265A1 (enExample) |
| CA (1) | CA2943367A1 (enExample) |
| ES (1) | ES2725951T3 (enExample) |
| WO (1) | WO2015148974A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US20070053996A1 (en) | 2005-07-22 | 2007-03-08 | Boyden Edward S | Light-activated cation channel and uses thereof |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| SG189813A1 (en) | 2008-04-23 | 2013-05-31 | Univ Leland Stanford Junior | Systems, methods and compositions for optical stimulation of target cells |
| EP2303405A4 (en) | 2008-06-17 | 2017-12-27 | The Board of Trustees of the Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
| US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| CN103491770B (zh) | 2010-11-05 | 2016-06-08 | 斯坦福大学托管董事会 | 稳定阶跃函数视蛋白及其使用方法 |
| EP3486253A1 (en) | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| EP3524676A1 (en) | 2011-12-16 | 2019-08-14 | The Board of Trustees of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| ES2628006T3 (es) | 2012-02-21 | 2017-08-01 | Circuit Therapeutics, Inc. | Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico |
| WO2016209654A1 (en) | 2015-06-22 | 2016-12-29 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and devices for imaging and/or optogenetic control of light-responsive neurons |
| WO2017015395A1 (en) | 2015-07-21 | 2017-01-26 | The Board Of Trustees Of The Leland Stanford Junior University | Carbon fiber optrodes for magnetic resonance imaging compatible optogenetics |
| EP3349851A4 (en) * | 2015-09-15 | 2019-04-24 | The Board of Trustees of the Leland Stanford Junior University | LIGHT-RESPONSIBLE POLYPEPTIDES AND METHOD OF USE THEREOF |
| US11294165B2 (en) | 2017-03-30 | 2022-04-05 | The Board Of Trustees Of The Leland Stanford Junior University | Modular, electro-optical device for increasing the imaging field of view using time-sequential capture |
| JP2021502101A (ja) * | 2017-11-10 | 2021-01-28 | ハワード ヒューズ メディカル インスティチュート | 修飾されたリガンド依存性イオンチャネルおよび使用の方法 |
| CN108192896B (zh) * | 2018-02-10 | 2021-05-07 | 中国烟草总公司郑州烟草研究院 | 一个烟草慢阴离子通道蛋白NtSLAH1及其应用 |
| US11858969B2 (en) | 2018-09-18 | 2024-01-02 | California Institute Of Technology | Engineered light-sensitive proteins |
| WO2020059675A1 (ja) * | 2018-09-20 | 2020-03-26 | 国立大学法人岩手大学 | 改変チャネルロドプシン |
| CN111263086A (zh) * | 2020-02-10 | 2020-06-09 | 江南大学 | 细胞融合的光电传感器的制作方法及其成像系统的工作方法 |
| US11921271B2 (en) | 2020-05-22 | 2024-03-05 | The Board Of Trustees Of The Leland Stanford Junior Univeristy | Multifocal macroscope for large field of view imaging of dynamic specimens |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
| US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| US5985930A (en) | 1996-11-21 | 1999-11-16 | Pasinetti; Giulio M. | Treatment of neurodegenerative conditions with nimesulide |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| WO1999011764A2 (en) | 1997-09-05 | 1999-03-11 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| DE60039766D1 (de) | 1999-08-09 | 2008-09-18 | Targeted Genetics Corp | Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen |
| US7632679B2 (en) | 2002-07-16 | 2009-12-15 | The Trustees Of Columbia University In The City Of New York | Systems and methods for screening for modulators of neural differentiation |
| US8926959B2 (en) | 2005-07-22 | 2015-01-06 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US20070053996A1 (en) | 2005-07-22 | 2007-03-08 | Boyden Edward S | Light-activated cation channel and uses thereof |
| US9274099B2 (en) | 2005-07-22 | 2016-03-01 | The Board Of Trustees Of The Leland Stanford Junior University | Screening test drugs to identify their effects on cell membrane voltage-gated ion channel |
| US10052497B2 (en) | 2005-07-22 | 2018-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| US9238150B2 (en) | 2005-07-22 | 2016-01-19 | The Board Of Trustees Of The Leland Stanford Junior University | Optical tissue interface method and apparatus for stimulating cells |
| DK2061891T3 (da) | 2006-08-24 | 2012-07-23 | Virovek Inc | Ekspression i insektceller af gener med overlappende åbne læserammer, fremgangsmåder og sammensætninger hertil |
| WO2008086470A1 (en) | 2007-01-10 | 2008-07-17 | The Board Of Trustees Of The Leland Stanford Junior University | System for optical stimulation of target cells |
| WO2008101128A1 (en) | 2007-02-14 | 2008-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | System, method and applications involving identification of biological circuits such as neurological characteristics |
| WO2008106694A2 (en) | 2007-03-01 | 2008-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Systems, methods and compositions for optical stimulation of target cells |
| US8545543B2 (en) | 2009-10-08 | 2013-10-01 | Massachusetts Institute Of Technology | Methods and apparatus for microstructure lightguides |
| US10035027B2 (en) | 2007-10-31 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Device and method for ultrasonic neuromodulation via stereotactic frame based technique |
| US10434327B2 (en) | 2007-10-31 | 2019-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Implantable optical stimulators |
| JP5544659B2 (ja) | 2008-03-24 | 2014-07-09 | 国立大学法人東北大学 | 改変された光受容体チャネル型ロドプシンタンパク質 |
| SG189813A1 (en) | 2008-04-23 | 2013-05-31 | Univ Leland Stanford Junior | Systems, methods and compositions for optical stimulation of target cells |
| JP5890176B2 (ja) | 2008-05-29 | 2016-03-22 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | セカンドメッセンジャーを光制御するためのセルライン、システム、および方法 |
| AU2009260029B2 (en) | 2008-06-17 | 2016-03-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods, systems and devices for optical stimulation of target cells using an optical transmission element |
| EP2303405A4 (en) | 2008-06-17 | 2017-12-27 | The Board of Trustees of the Leland Stanford Junior University | Apparatus and methods for controlling cellular development |
| US9101759B2 (en) | 2008-07-08 | 2015-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Materials and approaches for optical stimulation of the peripheral nervous system |
| NZ602416A (en) * | 2008-11-14 | 2014-08-29 | Univ Leland Stanford Junior | Optically-based stimulation of target cells and modifications thereto |
| JP5866332B2 (ja) | 2010-03-17 | 2016-02-17 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 感光性イオンを通過させる分子 |
| CA2817175C (en) | 2010-11-05 | 2019-09-24 | The Board Of Trustees Of The Leland Stanford Junior University | Upconversion of light using lanthanide-doped nanoparticles for use in optogenetic methods |
| CN106106368A (zh) | 2010-11-05 | 2016-11-16 | 斯坦福大学托管董事会 | 光控cns功能障碍 |
| US9992981B2 (en) | 2010-11-05 | 2018-06-12 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
| CA2816987C (en) | 2010-11-05 | 2018-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | Control and characterization of psychotic states |
| WO2012061681A1 (en) | 2010-11-05 | 2012-05-10 | The Board Of Trustees Of The Leland Stanford Junior University. | Control and characterization of memory function |
| CN103491770B (zh) | 2010-11-05 | 2016-06-08 | 斯坦福大学托管董事会 | 稳定阶跃函数视蛋白及其使用方法 |
| EP3486253A1 (en) * | 2010-11-05 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Light-activated chimeric opsins and methods of using the same |
| US8957028B2 (en) | 2010-11-13 | 2015-02-17 | Massachusetts Institute Of Technology | Red-shifted opsin molecules and uses thereof |
| US8696722B2 (en) | 2010-11-22 | 2014-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic magnetic resonance imaging |
| EP3524676A1 (en) | 2011-12-16 | 2019-08-14 | The Board of Trustees of The Leland Stanford Junior University | Opsin polypeptides and methods of use thereof |
| ES2628006T3 (es) | 2012-02-21 | 2017-08-01 | Circuit Therapeutics, Inc. | Composiciones para el tratamiento de trastornos neurogénicos del suelo pélvico |
| US20150040249A1 (en) | 2012-03-20 | 2015-02-05 | The Board Of Trustees Of The Leland Stanford Junior University | Non-Human Animal Models of Depression and Methods of Use Thereof |
| JP6580487B2 (ja) | 2012-11-21 | 2019-09-25 | サーキット セラピューティクス， インコーポレイテッド | 光遺伝学的治療のためのシステムおよび方法 |
| US10974064B2 (en) | 2013-03-15 | 2021-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of behavioral state |
| US9636380B2 (en) | 2013-03-15 | 2017-05-02 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of inputs to the ventral tegmental area |
| WO2014179331A2 (en) | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Devices, systems and methods for optogenetic modulation of action potentials in target cells |
| CA2921221A1 (en) | 2013-08-14 | 2015-02-19 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for controlling pain |
-
2015
- 2015-03-27 EP EP15770114.5A patent/EP3122761B1/en not_active Not-in-force
- 2015-03-27 JP JP2016559160A patent/JP2017511129A/ja not_active Ceased
- 2015-03-27 AU AU2015237265A patent/AU2015237265A1/en not_active Abandoned
- 2015-03-27 CN CN201580028022.1A patent/CN106459138A/zh active Pending
- 2015-03-27 ES ES15770114T patent/ES2725951T3/es active Active
- 2015-03-27 CA CA2943367A patent/CA2943367A1/en not_active Abandoned
- 2015-03-27 EP EP19156461.6A patent/EP3581580A1/en not_active Withdrawn
- 2015-03-27 WO PCT/US2015/023087 patent/WO2015148974A2/en not_active Ceased
- 2015-03-27 US US15/126,859 patent/US10052383B2/en active Active
-
2018
- 2018-08-07 US US16/057,639 patent/US10478499B2/en active Active
-
2019
- 2019-10-11 US US16/600,076 patent/US20200030446A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20200030446A1 (en) | 2020-01-30 |
| US20170095556A1 (en) | 2017-04-06 |
| JP2017511129A (ja) | 2017-04-20 |
| CN106459138A (zh) | 2017-02-22 |
| US20180344851A1 (en) | 2018-12-06 |
| US10052383B2 (en) | 2018-08-21 |
| WO2015148974A3 (en) | 2015-12-23 |
| AU2015237265A1 (en) | 2016-10-13 |
| US10478499B2 (en) | 2019-11-19 |
| ES2725951T3 (es) | 2019-09-30 |
| EP3122761A4 (en) | 2017-12-06 |
| EP3581580A1 (en) | 2019-12-18 |
| WO2015148974A2 (en) | 2015-10-01 |
| EP3122761A2 (en) | 2017-02-01 |
| EP3122761B1 (en) | 2019-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10478499B2 (en) | Engineered light-activated anion channel proteins and methods of use thereof | |
| US10220092B2 (en) | Devices, systems and methods for optogenetic modulation of action potentials in target cells | |
| US10538560B2 (en) | Opsin polypeptides and methods of use thereof | |
| US20200032291A1 (en) | Dopamine receptor type 2 specific promoter and methods of use thereof | |
| US9636380B2 (en) | Optogenetic control of inputs to the ventral tegmental area |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20211123 |
|
| FZDE | Discontinued |
Effective date: 20211123 |